SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T

Philipp E. Hartrampf,Thomas Hüttmann,Anna Katharina Seitz,Hubert Kübler,Sebastian E. Serfling,Wiebke Schlötelburg,Kerstin Michalski,Steven P. Rowe,Martin G. Pomper,Andreas K. Buck,Uta Eberlein,Rudolf A. Werner
DOI: https://doi.org/10.1007/s00259-023-06281-6
2023-06-06
Abstract:Quantification of [ 68 Ga]-labeled PSMA PET predicts response in patients with prostate cancer (PC) who undergo PSMA-targeted radioligand therapy (RLT). Given the increasing use [ 18 F]-labeled radiotracers, we aimed to determine whether the uptake derived from [ 18 F]PSMA-1007 PET can also identify responders and to assess its prognostic value relative to established clinical parameters.
What problem does this paper attempt to address?